Neurofibromin 1 (NF1) (NF1)

Neurofibromin 1 is a large cytoplasmic protein encoded by the NF1 gene that acts as a critical negative regulator of the Ras signaling pathway (UniProt P21359). It functions as a GTPase-activating protein (GAP) that accelerates the conversion of active Ras-GTP to inactive Ras-GDP, thereby suppressing downstream signaling through the MAPK/ERK and PI3K/Akt pathways (PubMed: 10757491). In the context of Schwann cells, the loss of NF1 leads to constitutive Ras activation, which is the primary driver for the formation of neurofibromas and malignant peripheral nerve sheath tumors (PubMed: 11834835). This signaling axis is the central therapeutic target for Neurofibromatosis type 1 (NF1), a genetic condition characterized by tumor predisposition and various neurodevelopmental symptoms (NIH: National Institute of Neurological Disorders and Stroke). Since restoring a tumor suppressor is challenging, current pharmacological interventions focus on inhibiting downstream nodes of the axis, particularly MEK1/2. Drugs like selumetinib have been successfully developed to treat plexiform neurofibromas by blocking the hyperactive Ras-MAPK cascade (FDA.gov). Therapeutic strategies also explore targeting other components of the axis, such as the PI3K/mTOR pathway or using farnesyltransferase inhibitors to prevent Ras membrane localization. Monitoring the axis often involves assessing the phosphorylation state of ERK as a readout of pathway activity. The specificity of this axis to Schwann cells in the context of neurofibromas makes it a high-priority area for precision oncology. Overall, the NF1-Ras axis represents a paradigm for targeting loss-of-function mutations through downstream pathway inhibition.

Other names

NeurofibrominNF-1Neurofibromatosis-related protein NF-1Watson syndrome protein

MEK1/2 inhibition, Ras-GTPase activation